Signature Estate & Investment Advisors LLC lifted its holdings in Incyte Co. (NASDAQ:INCY) by 22.1% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 16,363 shares of the biopharmaceutical company’s stock after buying an additional 2,965 shares during the period. Signature Estate & Investment Advisors LLC’s holdings in Incyte were worth $1,390,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of INCY. FMR LLC increased its holdings in shares of Incyte by 2,120.0% in the 1st quarter. FMR LLC now owns 657,610 shares of the biopharmaceutical company’s stock worth $56,561,000 after buying an additional 627,988 shares during the last quarter. Bessemer Group Inc. boosted its stake in shares of Incyte by 115,574.2% during the 2nd quarter. Bessemer Group Inc. now owns 564,490 shares of the biopharmaceutical company’s stock worth $47,959,000 after purchasing an additional 564,002 shares during the period. Eagle Asset Management Inc. purchased a new position in shares of Incyte during the 1st quarter worth about $37,747,000. Victory Capital Management Inc. boosted its stake in shares of Incyte by 13,339.9% during the 1st quarter. Victory Capital Management Inc. now owns 349,707 shares of the biopharmaceutical company’s stock worth $30,078,000 after purchasing an additional 347,105 shares during the period. Finally, Argent Capital Management LLC purchased a new position in shares of Incyte during the 1st quarter worth about $27,346,000. Hedge funds and other institutional investors own 90.47% of the company’s stock.

In other news, EVP Barry P. Flannelly sold 959 shares of the company’s stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $79.91, for a total value of $76,633.69. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jean Jacques Bienaime sold 1,724 shares of the company’s stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $85.07, for a total transaction of $146,660.68. Following the completion of the sale, the director now directly owns 277,597 shares of the company’s stock, valued at approximately $23,615,176.79. The disclosure for this sale can be found here. Insiders sold a total of 116,040 shares of company stock valued at $9,627,376 in the last ninety days. Corporate insiders own 17.10% of the company’s stock.

INCY has been the subject of a number of recent analyst reports. Piper Jaffray Companies reaffirmed a “buy” rating on shares of Incyte in a research note on Monday, June 17th. Cowen reaffirmed a “buy” rating on shares of Incyte in a research note on Sunday, August 4th. Barclays cut shares of Incyte from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $90.00 to $82.00 in a research note on Friday, May 3rd. Morgan Stanley lifted their price target on shares of Incyte from $81.00 to $82.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Finally, BidaskClub raised shares of Incyte from a “hold” rating to a “buy” rating in a research note on Friday, August 2nd. Twelve analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. Incyte presently has a consensus rating of “Buy” and an average price target of $89.67.

Shares of INCY traded down $0.39 during mid-day trading on Thursday, hitting $80.67. The company’s stock had a trading volume of 29,295 shares, compared to its average volume of 1,175,418. The company has a 50-day moving average price of $82.50. Incyte Co. has a 52-week low of $57.00 and a 52-week high of $89.30. The company has a market cap of $17.74 billion, a price-to-earnings ratio of 98.24 and a beta of 1.12. The company has a quick ratio of 5.59, a current ratio of 5.61 and a debt-to-equity ratio of 0.02.

Incyte (NASDAQ:INCY) last announced its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.37. Incyte had a net margin of 15.25% and a return on equity of 17.10%. The firm had revenue of $529.93 million during the quarter, compared to analysts’ expectations of $498.57 million. During the same quarter in the prior year, the company earned $0.63 EPS. The company’s revenue was up 1.6% compared to the same quarter last year. Research analysts expect that Incyte Co. will post 1.98 EPS for the current year.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.

Featured Story: What is the Difference Between Common Shares and Convertible Shares?

Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Co. (NASDAQ:INCY).

Institutional Ownership by Quarter for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.